SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 10-Q: (Original Filing)

[SKYSTAR BIO-PHARMACEUTICAL COMPANY FORM 10-Q INDEX Page Number 3 PART I. FINANCIAL INFORMATION Item 1. Financial Statements (unaudited) F-1] [CERTIFICATION I, Weibing Lu , certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of Skystar Bio-Pharmaceutical Company ; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATION I, , certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of Skystar Bio-Pharmaceutical Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact nece ssary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION Weibing Lu (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Weibing Lu Chief Executive Officer EX-32.1 5 v185379_ex32-1.htm] [CERTIFICATION (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Michael H. Lan Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 6 v185379_ex32-2.htm]

By | 2016-03-01T06:15:33+00:00 May 17th, 2010|Categories: Chinese Stocks, SEC Original, SKBI|Tags: , , , , , |0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 10-Q: SKYSTAR BIO-PHARMACEUTICAL COMPANY FORM 10-Q INDEX Page Number

[SKYSTAR BIO-PHARMACEUTICAL COMPANY FORM 10-Q INDEX Page Number 3 PART I. FINANCIAL INFORMATION Item 1. Financial Statements (unaudited) F-1] [CERTIFICATION I, Weibing Lu , certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of Skystar Bio-Pharmaceutical Company ; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATION I, , certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of Skystar Bio-Pharmaceutical Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact nece ssary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION Weibing Lu (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Weibing Lu Chief Executive Officer EX-32.1 5 v185379_ex32-1.htm] [CERTIFICATION (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Michael H. Lan Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 6 v185379_ex32-2.htm]

By | 2016-03-01T06:16:18+00:00 May 17th, 2010|Categories: Chinese Stocks, SKBI, Webplus ver|Tags: , , , , , |0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL] 10-Q: (Original Filing)

[SKYSTAR BIO-PHARMACEUTICALMPANY FORM10-Q INDEX Page Number 3 PART I.FINANCIAL INFORMATION Item 1. Financial Statements (unaudited) F-1nsolidated Balance Sheets of March 31, 2010 and December 31, 2009 F-1nsolidated Statements ofIncome and Othermprehensiveome for the Three Months Ended March 31, 2010 and 2009 F-2nsolidated Statements ofShareholders] [CERTIFICATION I, Weibing Lu , certify that: 1. I have reviewed this Quarterly Report on Form 10-Q ofystar Bio-Pharmaceuticalmpany ; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances] [CERTIFICATION I, , certify that: 1. I have reviewed this Quarterly Report on Form 10-Q ofystar Bio-Pharmaceuticalmpany; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact nece ssary to make the statements made, in light of the circumstances under which such] [CERTIFICATION Weibing Lu (2)The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. Weibing Lu Chief Executive Officer v185379_ex32-1.htm 5 EX-32.1] [CERTIFICATION (2)The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. Michael H. Lan Chief Financial Officer (Principal Financial and Accounting Officer) v185379_ex32-2.htm 6 EX-32.2]

By | 2016-02-05T04:21:38+00:00 May 17th, 2010|Categories: Chinese Stocks, SEC Original, SKBI|Tags: , , , , , |0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 8-K: (Original Filing)

[SKYSTAR COMMENCES TESTING ON TWO ADDITIONAL NEW PRODUCT DOSAGE FORMS TO FURTHER EXPAND THE COMPANY’S PRODUCT LINES The new dosage forms projected to generate $5 million in additional revenue by fiscal 2011 XI'AN, CHINA – May 12, 2010 - Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) ("Skystar" or the "Company"), The product testing process will ensure that the new dosage forms will adhere]

By | 2016-03-01T06:17:05+00:00 May 12th, 2010|Categories: Chinese Stocks, SEC Original, SKBI|Tags: , , , , , |0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 8-K: SKYSTAR COMMENCES TESTING ON TWO ADDITIONAL NEW PRODUCT

[SKYSTAR COMMENCES TESTING ON TWO ADDITIONAL NEW PRODUCT DOSAGE FORMS TO FURTHER EXPAND THE COMPANY’S PRODUCT LINES The new dosage forms projected to generate $5 million in additional revenue by fiscal 2011 XI'AN, CHINA – May 12, 2010 - Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) ("Skystar" or the "Company"), The product testing process will ensure that the new dosage forms will adhere]

By | 2016-03-01T06:17:48+00:00 May 12th, 2010|Categories: Chinese Stocks, SKBI, Webplus ver|Tags: , , , , , |0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL] 8-K: (Original Filing)

[SKYSTARMMENCES TESTING ON TWODITIONAL NEW PRODUCT DOSAGE FORMS TO FURTHER EXPAND THEMPANYS PRODUCT LINES The new dosage forms projected to generate $5 million inditional revenue by fiscal 2011 XI'AN, CHINA May 12, 2010 -ystar Bio-Pharmaceuticalmpany (NASDAQ:SKBI) ("Skystar" or the "Company"), The product testing process will ensure that the new dosage forms willhere to good manufacturing]

By | 2016-02-05T04:23:55+00:00 May 12th, 2010|Categories: Chinese Stocks, SEC Original, SKBI|Tags: , , , , , |0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL] 8-K: SKYSTARMMENCES TESTING ON TWODITIONAL NEW PRODUCT DOSAGE FORMS

[SKYSTARMMENCES TESTING ON TWODITIONAL NEW PRODUCT DOSAGE FORMS TO FURTHER EXPAND THEMPANYS PRODUCT LINES The new dosage forms projected to generate $5 million inditional revenue by fiscal 2011 XI'AN, CHINA May 12, 2010 -ystar Bio-Pharmaceuticalmpany (NASDAQ:SKBI) ("Skystar" or the "Company"), The product testing process will ensure that the new dosage forms willhere to good manufacturing]

By | 2016-02-05T04:24:46+00:00 May 12th, 2010|Categories: Chinese Stocks, SKBI, Webplus ver|Tags: , , , , , |0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 8-K: (Original Filing)

[EMPLOYMENT AGREEMENT Agreement Executive Company This EMPLOYMENT AGREEMENT (this “ WHEREAS, the Company desires to employ Executive as its Chief Financial Officer on the terms and conditions as set forth hereinafter, and Executive desires to be so employed; NOW, THEREFORE, IN CONSIDERATION of the foregoing facts, the mutual covenants and agreements contained herein and other good and valuable consideration, the] [SERVICES AGREEMENT 16 This SERVICES AGREEMENT (this “Agreement”), dated as of April RECITALS: B. The Parties have previously entered into an agreement setting forth the terms for the services of the Consultant as the Representative through March 31, 2010. C. At the request of the Company, the Consultant has continued to provide services to the Company as the Representative since] [SKYSTAR BIO-PHARMACEUTICAL COMPANY RESTRICTED STOCK AWARD AGREEMENT This Restricted Stock Award Agreement Agreement Company Grantee In consideration of the covenants herein set forth, the parties hereto agree as follows: Stock Award Information. 1. (a) Date of Award: April 16, 2010 (b) Grantee: R. Scott Cramer (c) Number of Shares: 10,000 (d) Original Value: $ (e) Amount Paid for Shares by] [SKYSTAR APPOINTS NEW CHIEF FINANCIAL OFFICER Michael H. Lan to Become Permanent CFO XI'AN, CHINA – April 19, 2010 - Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) ("Skystar" or the "Company"), Mr. Lan has advanced knowledge of U.S. GAAP and financial reporting requirements and has held internal financial control and audit positions with Silgan Containers Corporation and Gilead Sciences. Immediately prior to joining]

By | 2016-03-01T06:20:29+00:00 April 19th, 2010|Categories: Chinese Stocks, SEC Original, SKBI|Tags: , , , , , |0 Comments
Skip to toolbar